Which Patients Are Suitable for Taking Ixazomib?

Ixazomib is indicated for the treatment of multiple myeloma, a type of bone marrow cancer. Its mechanism of action involves inhibiting a protein that drives the growth and proliferation of cancer cells, thereby helping to slow down or prevent the spread of cancer cells.

Which Patients Are Suitable for Taking Ixazomib?

1. Ixazomib, in combination with lenalidomide and dexamethasone, is used for the treatment of multiple myeloma (a type of bone marrow cancer) in adult patients.

2. This combination therapy regimen is typically indicated as subsequent treatment for patients who have failed to respond to at least one other anticancer drug.

3. Ixazomib must not be used in patients receiving maintenance therapy or newly diagnosed patients with multiple myeloma, except for those participating in controlled clinical trials.

4. This product may also be used for other purposes not listed in this medication guide.

Important Precautions for Ixazomib

Anticancer drugs are potent agents and may cause numerous side effects. Before receiving treatment with this drug, ensure that you understand all the associated risks and benefits. It is crucial to maintain close cooperation with your doctor during the course of treatment.

Precautions for the Administration of Ixazomib

1. Take this medication strictly as directed by your doctor. Do not exceed the prescribed dose, take it more frequently, or continue the treatment beyond the duration specified by your doctor, as these actions may increase the risk of side effects.

2. This medication should be accompanied by a patient information leaflet. It is important to read and understand the information provided. If you have any questions, be sure to consult your doctor.

3. This medication should be taken once weekly at the same time on the same day each week, particularly during the first three weeks of treatment. The dose should be administered at least 1 hour before a meal or 2 hours after a meal.

4. Swallow the capsule whole with a full glass of water. Do not open, crush, or chew the capsule.

5. Handle crushed or broken capsules with caution. If accidental skin contact occurs, wash the affected area immediately with soap and water. If the drug gets into your eyes, rinse them thoroughly with water.

Mechanism of Action of Ixazomib

Ixazomib is classified as a proteasome inhibitor. The drug consists of an alanine-leucine dipeptide core and exerts a specific and reversible inhibitory effect on the 26S proteasome, as well as inhibiting the chymotrypsin-like subunit of the proteasome. This action ultimately disrupts cellular homeostasis, leading to the apoptosis of multiple myeloma cells that are either sensitive or resistant to other conventional therapies.

Absorption

Following oral administration, ixazomib reaches peak plasma concentrations within 1 hour, with a mean oral bioavailability of 58%. The drug is highly protein-bound.

Distribution

The steady-state volume of distribution of ixazomib is 543 liters.

Metabolism

The metabolism of ixazomib appears to occur through both CYP and non-CYP pathways, with no major CYP isoenzyme playing a dominant role. Non-cytochrome P450-mediated metabolism seems to be the primary elimination mechanism of ixazomib. At concentrations higher than clinical levels, ixazomib is metabolized by various CYP subtypes, with the estimated relative contribution in descending order being: 3A4, 1A2, 2B6, 2C8, 2D6, 2C19, and 2C9.

Elimination

Ixazomib is primarily excreted via urine (62%) and feces (22%). The terminal half-life of the drug is 9.5 days.